The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Recent advances in machine learning and experimental biology have offered breakthrough
solutions to problems such as protein structure prediction that were long thought to be …

Cancer immunotherapy works by stimulating and strengthening the body's anti-tumor
immune response to eliminate cancer cells. Over the past few decades, immunotherapy has …

Summary CD4 T follicular helper (TFH) cells support B cells, which are critical for germinal
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …

Although mutations in DNA are the best-studied source of neoantigens that determine
response to immune checkpoint blockade, alterations in RNA splicing within cancer cells …

T cell receptor (TCR) signal strength is a key determinant of T cell responses. We developed
a cancer mouse model in which tumor-specific CD8 T cells (TST cells) encounter tumor …